Many hemodialysis patients in Japan have symptoms of depression, but whether those patients are treated appropriately is unknown. As part of the Dialysis Outcomes and Practice Patterns Study, data on symptoms of depression, physician-diagnosed depression, prescribed medications, and death were collected prospectively in cohorts in Japan (n ¼ 1603) and 11 other countries (n ¼ 5872). Symptoms of depression were as prevalent in Japan as elsewhere, but in Japan a much smaller percentage of patients had physician-diagnosed depression: only 2% in Japan vs 17% elsewhere. Antidepressants were much less commonly prescribed in Japan: only 1% in Japan vs 17% elsewhere for patients with many and frequent symptoms of depression, and 16% in Japan vs 34% elsewhere for patients with physician-diagnosed depression. In Japan, symptoms of depression were associated with prescription of benzodiazepines (without antidepressants), and patients with physician-diagnosed depression were twice as likely to be given benzodiazepines: 32% in Japan vs 16% elsewhere. Benzodiazepine monotherapy was associated with death (relative risk 1.56, 95% confidence interval (CI), 1.25-1.94), even after adjustments for 13 likely confounders (relative risk 1.27, 95% CI, 1.01-1.59). Hemodialysis patients in Japan with symptoms of depression are given not antidepressants but benzodiazepines, a practice associated with higher mortality.
Many hemodialysis patients in Japan have symptoms of depression, but whether those patients are treated appropriately is unknown. As part of the Dialysis Outcomes and Practice Patterns Study, data on symptoms of depression, physician-diagnosed depression, prescribed medications, and death were collected prospectively in cohorts in Japan (n ¼ 1603) and 11 other countries (n ¼ 5872). Symptoms of depression were as prevalent in Japan as elsewhere, but in Japan a much smaller percentage of patients had physician-diagnosed depression: only 2% in Japan vs 17% elsewhere. Antidepressants were much less commonly prescribed in Japan: only 1% in Japan vs 17% elsewhere for patients with many and frequent symptoms of depression, and 16% in Japan vs 34% elsewhere for patients with physician-diagnosed depression. In Japan, symptoms of depression were associated with prescription of benzodiazepines (without antidepressants), and patients with physician-diagnosed depression were twice as likely to be given benzodiazepines: 32% in Japan vs 16% elsewhere. Benzodiazepine monotherapy was associated with death (relative risk 1.56, 95% confidence interval (CI), 1.25-1.94), even after adjustments for 13 likely confounders (relative risk 1.27, 95% CI, 1.01-1.59). Hemodialysis patients in Japan with symptoms of depression are given not antidepressants but benzodiazepines, a practice associated with higher mortality. Depression in hemodialysis patients is underdiagnosed. In 12 countries participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS), the number of patients with high scores on a standard questionnaire of symptoms of depression was more than three times the number in whom depression had been diagnosed by a physician. 1 Depression is also undertreated: of the DOPPS patients with physiciandiagnosed depression, only about one-third had been given a prescription for antidepressant medication, even though symptoms of depression were associated with withdrawal from treatment and with death. 1 In Japan, underdiagnosis was much more common than in any of the 11 other DOPPS countries, 1 but at the time of that study the data on medications given to DOPPS patients in Japan were not available. We obtained those data, and examined the prescription of antidepressants and benzodiazepines to hemodialysis patients in Japan. We also studied whether those prescriptions were associated with symptoms of depression, physician-diagnosed depression, hospitalization, and death.
RESULTS

Symptoms of depression
Symptoms of depression were common among patients in Japan: 40.0% had Center for Epidemiological Studies Depression Screening Index (CES-D) scores of 10 or greater, and 14.4% had scores of 15 or greater (Table 1 ). These did not differ markedly from the other DOPPS countries overall (43.9 and 19.5%, Table 1 ). Patients in Japan were no more or less likely than those in the other countries to have high CES-D scores (adjusted odds ratio, 0.97; 95% confidence interval (CI), 0.84-1.11).
Physician-diagnosed depression
Almost none of the patients in Japan had physiciandiagnosed depression (only 31 of 1603, 1.9%), but the comparable percentage in the other DOPPS countries was more than 17% (Table 1) . Patients in Japan were significantly less likely than those in the other countries to have physiciandiagnosed depression (adjusted odds ratio, 0.14; 95% CI, 0.09-0.21).
In addition, the connection between symptoms of depression and physician-diagnosed depression was weaker in Japan than in the other countries: physicians in the other countries diagnosed depression in 25.2% of patients with high CES-D scores, but physicians in Japan did so in less than 3% of such patients (Table 1) . Unlike in the other countries, in Japan there was no clear association between CES-D score and the diagnosis of depression ( Figure 1a ).
In Japan, the disparity between physician-diagnosed depression and symptoms of depression did not differ by the type of dialysis facility (private clinic vs hospital; 94.6 vs 92.4%; P40.05), but there was slightly less disparity in institutions that had a department of psychiatry (psychiatry department present vs absent; 86.7 vs 95.0%, Po0.05).
Prescription of antidepressants
In Japan, very few patients were given antidepressants (only 19 of 1603 patients, 1.2%). This was also true of those with high CES-D scores (only eight of 642 patients, 1.2%). The comparable percentages for the other DOPPS countries were more than 10 times higher: 12.8 and 17.2% (Table 1, Figure 1b ).
Even in patients with physician-diagnosed depression, prescription of antidepressants was only half as common in Japan as in the other countries: 16.1 vs 33.7% ( Table 1) .
Prescription of benzodiazepines
Benzodiazepines were prescribed to about one-fifth of the patients in Japan and to about one-seventh of those in the other DOPPS countries ( Table 1 ). In Japan, patients with physician-diagnosed depression were twice as likely as those in the other countries to be given benzodiazepines: 32.3 vs 15.7% (Table 1) .
Unlike in the other countries, in Japan patients who had high CES-D scores were almost twice as likely as those with lower scores to be given benzodiazepines: 26.6 vs 14.3% ( Table 1 ). The association between CES-D scores and prescription of benzodiazepines was stronger in Japan than in the other countries ( Figure 1c ).
Within Japan, patients who received benzodiazepines had lower five-item mental health index scores (indicating more symptoms of depression; adjusted odds ratio, 0.984, 95% CI, 0.980-0.988), but benzodiazepine prescription was not associated with albumin concentration (an indicator of end-stage renal disease severity; adjusted odds ratio, 0.906, 95% CI, 0.737-1.114).
Benzodiazepine prescribing practice also varied among dialysis facilities in Japan. At nine of the 59 facilities studied, no more than 10% of the patients with high CES-D scores were given benzodiazepines, but at 11 facilities more than 40% of the patients with high CES-D scores were given these drugs ( Figure 2 ). Japan had many facilities where patients with high CES-D scores were likely to be given benzodiazepines, but in the other countries such facilities were rare. Benzodiazepine prescribing practice was more uniform among dialysis facilities in the other countries than among facilities in Japan.
Adverse outcomes
CES-D scores were positively associated with the risk of hospitalization and of death ( Figure 3 ). Having received a prescription for a benzodiazepine was not associated with the risk of hospitalization, but it was associated with the risk of death ( Table 2) . That association remained even after adjusting for depression, and after adjusting for demographic and socioeconomic characteristics, time on dialysis, comorbid conditions, albumin, eKt/V, and hemoglobin ( Table 2 ). The risk of death was also greater at dialysis facilities that were above the median for the percentage of patients given benzodiazepines (hazard ratio, 1.36, 95% CI, 1.03-1.79).
DISCUSSION
Diagnosis of depression
The discrepancy between symptoms of depression and physician-diagnosed depression is greater in Japan than in other countries (Table 1, Figure 1a ). 1 To interpret this finding, we note first that the social stigmatization in Japan of people given the diagnosis of depression is well known. [2] [3] [4] [5] [6] In addition, a reluctance to identify depression can be found among the general public: when Japanese and Australians were given a vignette of someone with clear signs and symptoms of clinical depression and then asked to describe that person's condition, the Japanese were only one-third as likely as the Australians to use the term 'depression'. 7 In Japan, symptoms of depression may even 'be given positive social meanings'. 8 The Diagnostic and Statistical Manual is available in Japanese, but remaining to be studied in sufficient depth are the diagnostic criteria actually used by Japanese physicians when they encounter patients with symptoms of depression, how such practices differ between countries, and how they differ between physicians of different educational and clinical backgrounds. The relations of psychiatrists to their patients are changing, 9 and recognition and treatment of depression is improving among specialist providers of psychiatric services, 10 but nephrologists, even those who recognize clinical depression, might still not record the diagnosis. Symptoms of depression are often somatic, 3,6,11 and because renal failure affects many systems, nephrologists' task of distinguishing somatic symptoms of depression from 'direct' effects of renal failure is particularly complex. This might be alleviated if medical students and postgraduate trainees received better training in the diagnosis of mild and moderately severe psychiatric conditions.
One might expect the presence of a psychiatrist to make the diagnosis of depression more likely, and the present data do support that idea: in patients with high CES-D scores the diagnosis of depression was more common at dialysis facilities in institutions with a department of psychiatry. Such facilities accounted for one-quarter of the facilities studied in Japan. Thus, the percentage of hemodialysis patients to whom psychiatric services were readily available was small.
Of course, even if a psychiatrist is available and a patient is given a referral, the patient can still refuse consultation or treatment. The majority of people in Japan who experience a severe or moderate mental disorder do not seek medical The y axis indicates the percentage of facilities at which a given percentage of patients with CES-D scores of 10 or greater received prescriptions for benzodiazepines. For example, if a dialysis facility had 28 patients with CES-D scores of 10 or greater, and benzodiazepines were prescribed to 16 of those 28 patients (57%), then that facility would be included in the category '450-60'. In the present study, at 15.2% of dialysis facilities in Japan no more than 10% of the patients with high CES-D scores were given benzodiazepines, while at almost half of the facilities in Japan (49.2%; i.e. 30.5 þ 11.9 þ 5.1 þ 1.7) at least 30% of patients with high CES-D scores were given benzodiazepines. Facilities where benzodiazepines were prescribed to many of the patients with high CES-D scores were rare in the other DOPPS countries but they were common in Japan.
Benzodiazepine prescribing practice was also more uniform in the other DOPPS countries than in Japan.
treatment. 12 One reason may be found in the 2006 report by Shima and Satoh, 6 who noted that the stigma mentioned above 'continues to be associated with those suffering from mental disorders and for those who have to consult a psychiatrist'. In addition, among the general public in Japan psychiatrists are not commonly mentioned as people who would be helpful to someone with symptoms of depression: psychiatrists ranked fifth, behind counselors, close family, close friends, and social workers. 7
Underprescription of antidepressants
In the other DOPPS countries, antidepressants were prescribed to one-third of the patients with physician-diagnosed depression, but in Japan the comparable fraction was about one-sixth (Table 1) . That is, even after diagnosing depression, physicians in Japan were only half as likely to prescribe antidepressants as were physicians in other countries. Prescription of antidepressants is tied to socioeconomic and cultural forces, 8, 13 with the result that, in Japan, antidepressants are prescribed to patients with diagnosed depression at dosages that are below international standards. 14 That being the case in psychiatric settings, 14 physicians without psychiatric training may be even more reluctant to prescribe these drugs. Nephrologists might be unsure about the most appropriate doses and regimens, and about monitoring patients who receive antidepressants. The limited availability of psychiatric services (noted above) and reluctance to refer patients to outside institutions would make prescription of antidepressants even less likely.
Nephrologists might also avoid prescribing antidepressants because of anticholinergic effects: dry mouth could interfere with the restriction of fluid intake. Increased fluid intake might be seen as more dangerous than suboptimal treatment of recognized depression, but why that would be true only in Japan is unclear. We also note that the hypothesis that increased use of antidepressants would improve outcomes remains to be tested.
Possible substitution of benzodiazepines for antidepressants
We could not directly test the hypothesis that benzodiazepines were substituted for antidepressants, but the results in Table 1 and in Figures 1b, c, and 2 show that patients who might be expected to benefit from antidepressants were given not antidepressants but benzodiazepines. The benzodaizepines prescribed without antidepressants to those patients may have been intended as treatment, however inappropriate, for depression. They might also have been prescribed to treat pruritus, insomnia, 15 or anxiety. Even the possibility that some symptoms of depression reported by dialysis patients result from, or are aggravated by, benzodiazepine use should be considered. 10, 16 In Japan, when members of the general public were asked which drugs would be helpful for someone with symptoms of depression, about 30% indicated 'sleeping pills' and about 40% indicated 'tranquilizers'. 7 This public opinion is consistent with Japanese medical practice. Specifically, benzodiazepines are prescribed not only to about half of patients with depression who are under psychiatric care, 14 but also to patients with depressed mood who are seen in primary care. 8, 10 Because benzodiazpines are not indicated in the treatment of depression per se, 17, 18 one would expect to find only a few dialysis facilities where they were prescribed to large percentages of patients with high CES-D scores. That is exactly the pattern found in the countries other than Japan. In contrast, at many Japanese facilities benzodiazepines were prescribed to large percentages of such patients, which is consistent with the hypothesis that in Japan benzodiazepines are prescribed to treat symptoms of depression ( Figure 2) .
The practice of prescribing benzodiazepines to patients with symptoms of depression varied more widely among dialysis facilities in Japan than in other countries. Whether the variation in prescribing practice within Japan is related to variation in case mix, physician training, or other characteristics of the facilities remains to be studied, as does the hypothesis that the nine Japanese facilities at the left end of the x axis in Figure 2 should serve as models of good prescribing practice.
Adverse outcomes, and overall conclusions
Having a high CES-D score is a risk factor for hospitalization 1, 19 and for death among hemodialysis patients worldwide. 1 The present results show that symptoms of depression are important risk factors for those outcomes in Japanese patients in particular (Figure 3 ). Another new finding of the present study is that prescription of a benzodiazepine without prescription of an antidepressant is a risk factor for death. Benzodiazepines might have been prescribed as palliative care when patients were severely ill and already near death, but if such 'confounding by indication' did occur its effects were small: albumin concentration (an indicator of disease severity) was not associated with benzodiazepine prescription; facility-level analysis 20 also showed an association between benzodiazepines and the risk of death; and even after adjustment for age, albumin, comorbidities, and other likely confounders, the benzodiazepine-death association remained ( Table 2) . Although evidence reported recently suggests that symptoms of depression develop as a response to physical deterioration, 21 we must still be concerned about the dangers of not treating depression and of treating it inappropriately. For example, of great concern is the possibility that underlying the benzodiazepine-death association is a cause-effect relationship. Benzodiazepine-related deaths might be caused by these drugs' adverse cognitive and psychomotor effects. 17, 22, 23 We are now planning a case-bycase study of benzodiazepine prescription and causes of death.
Taken together, these findings suggest that outcomes could be improved if, as a minimum, dialysis patients with symptoms of depression are not given benzodiazepines inappropriately: primum non nocere. Hemodialysis clinics in Japan already have mortality rates that are much lower than those in the US and Europe. 24 Reconsideration of benzodiazepine prescribing practice, and of the treatment of patients who have symptoms of depression, might further reduce mortality.
We studied only dialysis patients, but depression is known to be a risk factor for death in patients with other chronic conditions as well, 25, 26 so the results regarding medications might be generalized to others. In general medical practice in Japan, the diagnosis of depression is not common [3] [4] [5] [6] 12 and benzodiazepines are prescribed to patients who would probably be given antidepressants if they were in Western countries. 8, 10, 14 Thus, even in patients not receiving dialysis, some prescriptions for benzodiazepines may need to be re-evaluated.
MATERIALS AND METHODS
Data were gathered between 1999 and 2004 in phases I and II of the DOPPS, an international, prospective, observational study of hemodialysis practice patterns and associated outcomes in Australia, Belgium, Canada, France, Germany, Italy, Japan, New Zealand, Spain, Sweden, the United Kingdom, and the United States. 27 Nationally representative samples of hemodialysis facilities were recruited in each country. Within each facility, study patients were randomly selected. Institutional review boards in each country approved the study, and informed consent was obtained from patients in accord with local requirements.
Baseline data regarding demographic factors, comorbid conditions, laboratory values, years since the onset of end-stage renal disease, and dialysis dose by equilibrated Kt/V (eKt/V) were collected upon patient entry into the study. Each patient's medical record was assessed for physician-diagnosed depression within the past 12 months. This was recorded along with the listed name, dosage, and frequency of any medication(s) prescribed on or before entry into the study.
Patients entering phase II of the DOPPS were asked to complete the 10-item version of the CES-D, which was used to quantify the number and frequency of symptoms of depression during the past week. 28, 29 Each response is coded on a scale from 0 to 3; the CES-D score (0-30) is the sum of the item scores. Higher scores indicate more symptoms, and more frequent symptoms, of depression. High CES-D scores were defined as those X10. 1, 29, 30 As another measure of symptoms of depression, the five-item mental health index of the SF-36 [31] [32] [33] was completed by patients in both the DOPPS I and DOPPS II in Japan.
Primary analyses involving baseline patient characteristics were restricted to the initial prevalent cross-sectional sample of 1603 DOPPS II Japanese patients with information on depression diagnosis and a calculable CES-D score. We also compared the Japanese sample with a similarly sampled initial cross-section of 5872 patients from the other DOPPS countries. Statistical modeling for time-to-event analyses utilized the entire DOPPS II Japanese sample of 1938 patients.
Logistic regression techniques were used to estimate associations between baseline patient characteristics and indicators of depression. Univariate models involving only one explanatory variable were calculated for physician-diagnosed depression, because its prevalence was low. For associations with patient-reported symptoms of depression, we used multivariate models accounting for clustering and adjusted for age, sex, years on dialysis, living arrangement status, marital status, educational attainment, employment status, household income, 12 summary comorbid conditions, eKt/V, hemoglobin, and serum albumin.
Cox proportional hazards models were used to examine associations between indicators of depression and outcomes (hospitalization and all-cause mortality). Withdrawal from dialysis was not analyzed because the number of events was too low (only eight in Japan). Except where noted otherwise, all models accounted for clustering effects and were adjusted for the variables listed above.
Analyses of benzodiazepine prescription as a predictor of hospitalization and of death were also performed with Cox proportional hazards models, using data from Japan DOPPS I and II (n ¼ 5041). As indicated in Table 2 , four models were used: (1) unadjusted; (2) adjusted for the five-item mental health index score; (3) same as no. 2, but also adjusted for age, sex, time on dialysis, socioeconomic factors (living alone, married, educational status, employment status, and household income), and the presence or absence of 12 comorbid conditions; and (4) same as no. 3, but also adjusted for serum albumin, hemoglobin, and eKt/V. Logistic regression with benzodiazepine prescription as the outcome also included the variables mentioned above.
We considered prescription of an antidepressant to indicate that clinical depression had been recognized and was being treated as such. When analyzing prescription of benzodiazepines, we wanted to focus on patients in whom clinical depression either was not recognized or was not treated with antidepressant medication. Therefore, results regarding prescription of benzodiazepines do not include data from patients treated with both benzodiazepines and antidepressants. 17, 34 To quantify disparities between symptoms of depression and physician-diagnosed depression at the facility level, we computed 1 minus the ratio of the number of patients at the facility with physician-diagnosed depression to the number at the same facility with a CES-D score of 10 or greater, and expressed the result as a percentage. For each facility, to the degree that the number of patients with high CES-D scores exceeds the number with physiciandiagnosed depression, the value of this 'disparity index' for that facility approaches 100%.
All statistical analyses were performed with SAS software, version 9.1 (SAS Institute; Cary, NC, USA).
